CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life.
Bladder Cancer Patient
I am a bladder cancer patient/caregiver looking for more information
Healthcare Provider
I am a healthcare provider looking for more information
Clinical Trials
CG Oncology has a robust clinical trials program to study the safety and efficacy of cretostimogene grenadenorepvec. It is being investigated in multiple studies across the NMIBC landscape.
Resources
Download our resources to learn more about our work in developing a bladder-sparing therapeutic option for those affected by bladder cancer.
